NCT05052931 - Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Gastric Cancer

Interventions

DRUG

Nab-paclitaxel combined with oxaliplatin and S-1

Nab-paclitaxel 100mg/m\^2, D1, Q3W; oxaliplatin 85 mg/m\^2, D1, Q3W; S-1 60 mg/m\^2, D1-14, Q3W; Neoadjuvant chemotherapy 2 cycles, followed by surgery, continue to receive 6 cycles of adjuvant chemotherapy.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of the Air Force Medical University, Xi'an